OpenSourceMalaria:Other GSK Series Under Consideration: Difference between revisions
(added hyperlinks) |
|||
Line 11: | Line 11: | ||
ClC(C=C1)=CC=C1OC2=CC=CC=C2NC(C(C)(C)C)=O | ClC(C=C1)=CC=C1OC2=CC=CC=C2NC(C(C)(C)C)=O | ||
Citations for exact structure search: | '''Citations for exact structure search:''' <br> | ||
DOI:10.1021/ml200135p – GSK Paper on Open Innovation | 1. [http://pubs.acs.org/doi/abs/10.1021/ml200135p DOI:10.1021/ml200135p] – GSK Paper on Open Innovation | ||
WO 1994-GB1409 – Preparation of anti-atherosclerotic diaryl compound, The Wellcome Foundation <br> | 2. WO 1994-GB1409 – Preparation of anti-atherosclerotic diaryl compound, The Wellcome Foundation <br> | ||
''Atherosclerosis – The clogging or hardening of arteries or blood vessels caused by plaques (accumulations of fatty deposits, usually cholesterol'' <br> | ''Atherosclerosis – The clogging or hardening of arteries or blood vessels caused by plaques (accumulations of fatty deposits, usually cholesterol'' <br> | ||
InChi Search: | '''InChi Search:''' <br> | ||
No hits on Google | No hits on Google | ||
Citations for sub-structure search: | '''Citations for sub-structure search:''' <br> | ||
WO 2000-EP1224 – Preparation of phenyl and pyridinyl derivatives as NK-1 receptor antagonists, | 1. WO 2000-EP1224 – Preparation of phenyl and pyridinyl derivatives as NK-1 receptor antagonists, F. Hoffmann La Roche <br> | ||
''Neurokinin 1 (NK), Antagonists – Novel class of medication possessing antidepressant, anxiolytic and antiemetic action'' <br> | ''Neurokinin 1 (NK), Antagonists – Novel class of medication possessing antidepressant, anxiolytic and antiemetic action'' <br> | ||
ComGenex Compound (Scheme 2) | 2. ComGenex Compound (Scheme 2) | ||
[[Image:ComGenex.png|thumb|center|540px|Scheme 2: ComGenex Compound]] <br> | [[Image:ComGenex.png|thumb|center|540px|Scheme 2: ComGenex Compound]] <br> | ||
InChI=1S/C17H17Cl2NO2/c1-17(2,3)16(21)20-13-6-4-5-7-15(13)22-14-9-8-11(18)10-12(14)19/h4-10H,1-3H3,(H,20,21) | InChI=1S/C17H17Cl2NO2/c1-17(2,3)16(21)20-13-6-4-5-7-15(13)22-14-9-8-11(18)10-12(14)19/h4-10H,1-3H3,(H,20,21) | ||
ClC(C=C1)=CC(Cl)=C1OC2=CC=CC=C2NC(C(C)(C)C)=O | ClC(C=C1)=CC(Cl)=C1OC2=CC=CC=C2NC(C(C)(C)C)=O |
Revision as of 17:57, 12 May 2013
Other GSK Series Under Consideration
The team have focused on the synthesis and evaluation of two series (the aryl pyrroles and aminothienopyrimidines) to date. The focus of the project could change quite rapidly following the receipt of new biological data (for highly active or inactive compounds). This page highlights other GSK compounds from the TCAMS data that look attractive.
TCMDC 137332
InChI=1S/C17H18ClNO2/c1-17(2,3)16(20)19-14-6-4-5-7-15(14)21-13-10-8-12(18)9-11-13/h4-11H,1-3H3,(H,19,20) ClC(C=C1)=CC=C1OC2=CC=CC=C2NC(C(C)(C)C)=O
Citations for exact structure search:
1. DOI:10.1021/ml200135p – GSK Paper on Open Innovation
2. WO 1994-GB1409 – Preparation of anti-atherosclerotic diaryl compound, The Wellcome Foundation
Atherosclerosis – The clogging or hardening of arteries or blood vessels caused by plaques (accumulations of fatty deposits, usually cholesterol
InChi Search:
No hits on Google
Citations for sub-structure search:
1. WO 2000-EP1224 – Preparation of phenyl and pyridinyl derivatives as NK-1 receptor antagonists, F. Hoffmann La Roche
Neurokinin 1 (NK), Antagonists – Novel class of medication possessing antidepressant, anxiolytic and antiemetic action
2. ComGenex Compound (Scheme 2)
InChI=1S/C17H17Cl2NO2/c1-17(2,3)16(21)20-13-6-4-5-7-15(13)22-14-9-8-11(18)10-12(14)19/h4-10H,1-3H3,(H,20,21) ClC(C=C1)=CC(Cl)=C1OC2=CC=CC=C2NC(C(C)(C)C)=O